Sanofi Share Price Today | Stock Price & Sanofi Share Screener
As of October 5, 2026, the live Sanofi share price (NSE: SANOFI) is ₹3,024.20 on NSE and ₹3,025.30 on BSE, down 0.43% from the previous close, with shares trading between ₹3,016.80 and ₹3,069.00 in today's trading session, and a 52-week range of ₹3,024.20–₹4,807.10. Check Sanofi yearly highs lows for the annual price range and momentum. Use the Sanofi stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Sanofi opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹539 and net income of ₹120, with EBITDA of ₹175, an operating margin of 32.0% and a profit margin of 22.3%.
Sanofi Share Price Chart
Track the current stock price of Sanofi with an interactive chart. Analyse SANOFI share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Sanofi stock quote in one place.
The quote of ₹3,024.20 sits between the 52-week low of ₹3,024.20 and the 52-week high of ₹4,807.10, and the latest session moved -0.43% from the previous close.
Sanofi Company Profile - Fundamental Screener
Screen Sanofi company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SANOFI shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, with Rahul Bhatnagar listed as chairperson or CEO, and it trades under ISIN INE058A01010.
Business Overview
Sanofi India Limited is a pharmaceutical company primarily engaged in manufacturing and trading drugs and pharmaceuticals. It operates manufacturing facilities in Goa and Ankleshwar, Gujarat, and sells products through independent distributors mainly in India. The company focuses on five therapeutic areas: diabetes, epilepsy, cardiology, allergy, and pain care. Key products...more
Company Details
Classification
Identifiers and Leadership
Sanofi Balance Sheet Screener
Screen SANOFI balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2024, total assets were ₹1,612, down from ₹1,715 in 2023.
Latest statistics put total assets at ₹1,612 and shareholder funds at ₹861, with a leverage ratio of 0.02.
| Item | 2024 | 2023 |
|---|---|---|
Assets |
||
| Total Assets | 1,612 | 1,715 |
| Current Assets | 1,127 | 1,248 |
| Fixed Assets | 313 | 315 |
Liabilities |
||
| Total Liabilities | 0 | 0 |
| Current Liabilities | 32 | 48 |
| Non-Current Liabilities | 0 | 0 |
Shareholders' Equity |
||
| Total Equity | 861 | 1,015 |
| Share Capital | 23 | 23 |
| Reserves & Surplus | 838 | 992 |
Sanofi Income Statement Screener - Profit & Revenue Analysis
Screen Sanofi income statement and profit fundamentals. Analyze SANOFI quarterly results. Sanofi reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2025-Mar, revenue was ₹539 and net profit was ₹120, equal to earnings per unit of ₹51.89, at an operating margin of 32%.
In that period expenses were ₹364, interest cost ₹0 and tax ₹46. The next period listed, 2024-Dec, shows revenue of ₹529 and net profit of ₹91.
| Item | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar |
|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||
| Revenue | 539 | 529 | 526 | 503 | 579 | 547 | 573 | 572 | 622 |
| Expenses | 364 | 397 | 404 | 367 | 400 | 370 | 377 | 393 | 368 |
Operating Costs and Margins | |||||||||
| EBITDA | 175 | 132 | 122 | 137 | 179 | 177 | 195 | 179 | 254 |
| Operating Profit % | 32.00% | 23.00% | 23.00% | 21.00% | 22.00% | 21.00% | 23.00% | 24.00% | 29.00% |
| Depreciation | 10 | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Profit and Earnings | |||||||||
| Profit Before Tax | 165 | 122 | 113 | 127 | 169 | 167 | 186 | 169 | 244 |
| Tax | 46 | 31 | 30 | 24 | 33 | 30 | 34 | 46 | 54 |
| Net Profit | 120 | 91 | 82 | 103 | 137 | 138 | 152 | 123 | 190 |
| EPS | 51.89 | 39.64 | 35.69 | 44.81 | 59.31 | 59.79 | 65.95 | 53.37 | 82.78 |
Sanofi Cash Flow Screener - Liquidity Fundamentals
Screen SANOFI cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2024-March, operating activities generated ₹462, and net cash flow was an outflow of ₹111.
Over the same period, investing activities used ₹180 and financing activities used ₹392.
| Item | 2024-March | 2023-March |
|---|---|---|
Cash from Operations and Investing | ||
| Operating Activities | 462 | 230 |
| Investing Activities | -180 | 38 |
Financing and Net Cash | ||
| Financing Activities | -392 | -878 |
| Net Cash Flow | -111 | -610 |
Sanofi Shareholding Pattern Screener
See Sanofi shareholding pattern with promoter, FII, and DII holdings. Check Sanofi promoter holding and ownership changes for SANOFI on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 60.40%, foreign institutions 5.64%, domestic institutions 21.13% and the public 10.19%, spread across 75,758 shareholders.
The shareholder count was 75,758 in 2026-Mar, compared with 80,005 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% |
Institutional Investors | ||||||||
| FII Holding | 5.64% | 5.69% | 5.57% | 5.61% | 5.57% | 5.55% | 6.11% | 5.81% |
| DII Holding | 21.13% | 19.86% | 23.02% | 23.06% | 22.29% | 21.31% | 23.08% | 22.79% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 10.19% | 11.38% | 8.38% | 8.33% | 9.08% | 10.02% | 7.97% | 8.31% |
| Other Holding | 2.64% | 2.67% | 2.63% | 2.61% | 2.67% | 2.73% | 2.44% | 2.69% |
| Shareholder Count | 75,758 | 80,005 | 68,196 | 66,790 | 71,395 | 75,813 | 61,849 | 67,662 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Sanofi. Sanofi dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹123.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹123.00 and ₹117.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹123.00 | 3.83% |
| 2024-March | ₹117.00 | 2.04% |
| 2023-March | ₹167.00 | 2.06% |
| 2022-March | ₹570.00 | 10.15% |
| 2021-March | ₹490.00 | 6.53% |
| 2020-March | ₹365.00 | 4.63% |
| 2019-March | ₹349.00 | 5.58% |
| 2018-March | ₹84.00 | 1.44% |
| 2017-March | ₹71.00 | 1.37% |
Sanofi Stock Index Membership - Nifty & Sensex
See which indices include Sanofi stock. Check SANOFI index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 9 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX MSL400.
Complete Index List
Sanofi Market Events Screener - Corporate Actions
Get Sanofi corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Sanofi stock events that may affect SANOFI share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated August 4, 2026, with a record date of August 4, 2026.
It is followed by Annual General Meeting dated April 29, 2026 and Quarterly Result Announcement dated April 28, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-04 | 2026-08-04 | Quarterly Result Announcement | NA | -0.78% |
| 2026-04-29 | 2026-04-29 | Annual General Meeting | NA | 6.74% |
| 2026-04-28 | 2026-04-28 | Quarterly Result Announcement | NA | -3.56% |
| 2026-04-22 | 2026-04-22 | Dividend | ₹ 48.00 /share | -12.03% |
| 2026-02-25 | 2026-02-25 | Quarterly Result Announcement | NA | 1.74% |
| 2025-11-07 | 2025-11-07 | Dividend | ₹ 75.00 /share | -0.03% |
| 2025-10-29 | 2025-10-29 | Quarterly Result Announcement | NA | -0.56% |
| 2025-07-31 | 2025-07-31 | Quarterly Result Announcement | NA | -1.24% |
| 2025-05-15 | 2025-05-15 | Annual General Meeting | NA | 8.52% |
| 2025-05-14 | 2025-05-14 | Quarterly Result Announcement | NA | 3.02% |
| 2025-04-25 | 2025-04-25 | Dividend | ₹ 117.00 /share | 29.86% |
| 2025-02-27 | 2025-02-27 | Quarterly Result Announcement | NA | -5.58% |
| 2024-11-07 | 2024-11-07 | Quarterly Result Announcement | NA | -6.28% |
| 2024-05-14 | 2024-05-14 | Annual General Meeting | NA | -13.18% |
| 2024-05-03 | 2024-05-03 | Dividend | ₹ 117.00 /share | -5.75% |
Sanofi Competitors Screener - Peer Stocks Comparison
Screen SANOFI competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 432,120 | 36.04 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 245,532 | 84.24 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 181,333 | 84.71 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 114,284 | 25.27 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 108,576 | 32.50 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 107,198 | 98.20 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 104,707 | 50.04 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,679 | 32.41 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,479 | 25.84 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 92,885 | 16.82 | 29,039 | 26.75% | 5,356 | 31.59 |
Sanofi Company Announcements - News & Reports Screener
Screen SANOFI latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 2, 2026.
The next most recent announcements are dated October 1, 2026 and October 1, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-02 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-10-01 | Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011 | - |
| 2026-10-01 | Disclosure Under Regulation 7(2)(B) Of The SEBI (Prohibition Of Insider Trading) Regulations 2015 | - |
| 2026-10-01 | Disclosure Under Regulation 7(2)(B) Of The SEBI (Prohibition Of Insider Trading) Regulations 2015 | - |
| 2026-09-28 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-09-28 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-09-28 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-09-28 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 | - |
| 2026-09-28 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-09-28 | Closure of Trading Window | - |
| 2026-09-21 | Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-09-18 | Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations 2011 | - |
| 2026-09-08 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-08-31 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Receipt Of Show Cause Notice From GST Authorities | - |
| 2026-08-13 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-08-11 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-08-10 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-08-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-08-05 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-05 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹3,024.20, within a 52-week range of ₹3,024.20 to ₹4,807.10. The P/E ratio is 20.14 and the P/B ratio is 8.19, with earnings per unit of ₹179.46. Market capitalisation stands at ₹6,995.32 Cr and the dividend yield is 3.54%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 6, 2026. This page covers 2 balance sheet periods, 9 income statement periods, 2 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.